Keyphrases
Genetic Modification
100%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
100%
IDH-mutant Glioma
100%
Hazard Ratio
85%
Overall Survival
85%
Radiation Dose
28%
Glioblastoma
28%
CDKN2B
28%
TERT Promoter mutation
28%
Next-generation Sequencing
14%
Poor Outcome
14%
Treatment Options
14%
Poor Prognosis
14%
Patient Characteristics
14%
Multivariable
14%
Poor Survival
14%
Genetic Markers
14%
Cox Proportional Hazard Analysis
14%
Patient Variables
14%
Low-dose Radiation
14%
Dose Fractionation
14%
Tumor Genetics
14%
Fractionation Scheme
14%
Patient-specific Treatment
14%
Alteration Characteristics
14%
NF1 mutation
14%
CDKN2A mutation
14%
Medicine and Dentistry
Gene Mutation
100%
Hazard Ratio
100%
Glioblastoma
100%
Overall Survival
100%
Neoplasm
16%
Next Generation Sequencing
16%
Proportional Hazards Model
16%
Clinician
16%
Patient Characteristics
16%
Radiation Dose Fractionation
16%
Genetic Marker
16%
Biochemistry, Genetics and Molecular Biology
Gene Mutation
100%
Wild Type
100%
Overall Survival
100%
CDKN2B
33%
Next Generation Sequencing
16%
Fractionation
16%
Genetic Marker
16%
Immunology and Microbiology
Gene Mutation
100%
Wild Type
100%
Overall Survival
100%
Fractionation
16%
Genetic Marker
16%
Next Generation Sequencing
16%